Happy to share our manuscript titled 'Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy' published in JAMA Oncology!
@jama.com
jamanetwork.com/journals/jam...
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Great review! NECTIN4 is an exciting target. More to come !
#cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker
Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24
Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social
